A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

Carlos Becerra,Alexander I. Spira,Paul R. Conkling,Stephen Lane Richey,Wahid T. Hanna,Gregory M. Cote,Rebecca S. Heist,Adrian Langleben,Scott A. Laurie,William Jeffery Edenfield,Kimiko Kossler,Stephanie Hume,Youzhi Li,Matthew Hitron,Chiang Li

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

2016

Carlos Becerra
Alexander I. Spira
Paul R. Conkling
Stephen Lane Richey
Wahid T. Hanna
Gregory M. Cote
Rebecca S. Heist
Adrian Langleben
Scott A. Laurie
William Jeffery Edenfield
Kimiko Kossler
Stephanie Hume
Youzhi Li
Matthew Hitron
Chiang Li

9093Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that works throughinhibiting the STAT3pathway, and it has shown potent synergistic anti-tumor activity w...

Keywords:

Cancer
Napabucasin
Cell
Lung cancer
Pathology
Paclitaxel
Cancer research
Medicine
STAT3
non small cell
weekly paclitaxel

Correction
Source
Cite
Save

References

Citations